亚胺培南西司他丁钠在重症肺炎患者中的应用效果及不良反应发生率分析  

Application Effect and Incidence of Adverse Reactions of Imipenem and Cilastatin Sodium in Patients with Severe Pneumonia

作　　者：郭晶[1] 张民伟[1] GUO Jing;ZHANG Minwei(Department of Critical Care Medicine,the First Affiliated Hospital of Xiamen University,Xiamen 361000,Fujian,China)

机构地区：[1]厦门大学附属第一医院重症医学科,福建厦门361000

出　　处：《中国药物滥用防治杂志》2021年第6期903-906,共4页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:研究亚胺培南西司他丁钠在重症肺炎患者中的应用效果及不良反应发生率。方法:选取我院2018年1月—2020年8月诊治的重症肺炎患者186例为研究对象,以随机数字表法分为对照组和观察组,每组93例。对照组给予对症支持治疗和头孢哌酮舒巴坦抗感染治疗,观察组在对照组基础上加用亚胺培南西司他丁钠抗治疗,比较两组临床疗效、不良反应发生率、炎症因子水平、肝功能指标。结果:观察组治疗总有效率为95.70%,高于对照组的87.10%,差异有统计学意义(P<0.05);观察组不良反应发生率为6.45%,与对照组的7.53%比较,差异无统计学意义(P>0.05);观察组治疗7 d后的白细胞计数、PCT水平和CRP水平均低于对照组,差异有统计学意义(P<0.05);两组治疗前、治疗7 d后的ALT水平比较,差异无统计学意义(P>0.05)。结论:亚胺培南西司他丁钠在重症肺炎治疗中应用效果显著,能有效促进炎症反应控制,对肝功能影响小,且安全高,值得推广。Objective:To study the application effect and incidence of adverse reactions of imipenem and cilastatin sodium in patients with severe pneumonia.Methods:A total of 186 patients with severe pneumonia diagnosed and treated in our hospital from January 2018 to August 2020 were selected and divided into control group and observation group by random number table method,with 93 cases in each group.The control group was given symptomatic support treatment and cefoperazone sulbactam anti-infection treatment,while the observation group was given imipenem and cilastatin sodium anti-infection treatment on the basis of the control group.The clinical efficacy,incidence of adverse reactions,levels of inflammatory factors and liver function indexes of the two groups were compared.Results:The total effective rate of the observation group was 95.70%,which was higher than 87.10%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 6.45%,which was not significantly different from 7.53%in the control group(P>0.05).The white blood cell count,PCT level and CRP level in the observation group after 7 days of treatment were lower than those in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in ALT level between the two groups before and 7 days after treatment(P>0.05).Conclusion:TImipenem cilastatin sodium is effective in the treatment of severe pneumonia,which can effectively promote the control of inflammatory response,has little effect on liver function,and is safe and worthy of promotion.

关 键 词：重症肺炎 头孢哌酮舒巴坦 亚胺培南西司他丁钠 不良反应 炎症因子 

分 类 号：R969.3[医药卫生—药理学]